Affinium is a clinical-stage, specialty pharmaceutical company developing a novel class of antibiotics that targets the bacterial fatty acid synthesis pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.
Established in 2000, Affinium has focused on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. Affinium has an international patent portfolio of more than 1,700 compounds, bacterial targets and assays in this new therapeutic class. Affinium’s first clinical candidate, AFN-1252, has demonstrated successful proof of concept in over man (>200 subjects) with an oral tablet, showing good safety and tolerability in four Phase 1 studies, and excellent efficacy and safety in a Phase 2a study of acute bacterial skin and skin structure infections due to staphylococci. An IV formulation will enter clinical trials in 2013.